{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:38:03Z","timestamp":1794980283822,"version":"4.9.1"},"reference-count":201,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Despite an increase in the number of therapies available to treat patients with immune thrombocytopenia (ITP), there are minimal data from randomized trials to assist physicians with the management of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the management of ITP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In 2015, ASH formed a multidisciplinary guideline panel that included 8 adult clinical experts, 5 pediatric clinical experts, 2 methodologists with expertise in ITP, and 2 patient representatives. The panel was balanced to minimize potential bias from conflicts of interest. The panel reviewed the ASH 2011 guideline recommendations and prioritized questions. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including evidence-to-decision frameworks, to appraise evidence (up to May 2017) and formulate recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The panel agreed on 21 recommendations covering management of ITP in adults and children with newly diagnosed, persistent, and chronic disease refractory to first-line therapy who have non\u2013life-threatening bleeding. Management approaches included: observation, corticosteroids, IV immunoglobulin, anti-D immunoglobulin, rituximab, splenectomy, and thrombopoietin receptor agonists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>There was a lack of evidence to support strong recommendations for various management approaches. In general, strategies that avoided medication side effects were favored. A large focus was placed on shared decision-making, especially with regard to second-line therapy. Future research should apply standard corticosteroid-dosing regimens, report patient-reported outcomes, and include cost-analysis evaluations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2019000966","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T12:41:43Z","timestamp":1575376903000},"page":"3829-3866","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1339,"title":["American Society of Hematology 2019 guidelines for immune thrombocytopenia"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6753-6107","authenticated-orcid":false,"given":"Cindy","family":"Neunert","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Columbia University Irving Medical Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0794-5851","authenticated-orcid":false,"given":"Deirdra R.","family":"Terrell","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald M.","family":"Arnold","sequence":"additional","affiliation":[{"name":"Division of Hematology and Thromboembolism, Department of Medicine, and"},{"name":"McMaster Centre for Transfusion Research, McMaster University, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Buchanan","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, University of Texas Southwestern Medical Center, Dallas, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5986-504X","authenticated-orcid":false,"given":"Douglas B.","family":"Cines","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichola","family":"Cooper","sequence":"additional","affiliation":[{"name":"Centre for Haematology, Department of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Cuker","sequence":"additional","affiliation":[{"name":"Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny M.","family":"Despotovic","sequence":"additional","affiliation":[{"name":"Section of Hematology-Oncology, Department of Pediatrics, College of Medicine, Baylor University, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4243-2691","authenticated-orcid":false,"given":"James N.","family":"George","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-0449","authenticated-orcid":false,"given":"Rachael F.","family":"Grace","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Department of Pediatrics, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"K\u00fchne","sequence":"additional","affiliation":[{"name":"University Children\u2019s Hospital Basel, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Kuter","sequence":"additional","affiliation":[{"name":"Department of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2508-1786","authenticated-orcid":false,"given":"Wendy","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R.","family":"McCrae","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pruitt","sequence":"additional","affiliation":[{"name":"Coral Gables, FL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Shimanek","sequence":"additional","affiliation":[{"name":"Ames, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3448-0156","authenticated-orcid":false,"given":"Sara K.","family":"Vesely","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,12,3]]},"reference":[{"issue":"3","key":"2020011013391107100_B1","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1503\/cmaj.131237","article-title":"Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise","volume":"186","author":"Sch\u00fcnemann","year":"2014","journal-title":"CMAJ"},{"key":"2020011013391107100_B2","volume-title":"Clinical Practice Guidelines We Can Trust","author":"Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines","year":"2011"},{"issue":"7","key":"2020011013391107100_B3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-156-7-201204030-00009","article-title":"Guidelines International Network: toward international standards for clinical practice guidelines","volume":"156","author":"Qaseem","year":"2012","journal-title":"Ann Intern Med"},{"issue":"7","key":"2020011013391107100_B4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.7326\/M14-1885","article-title":"Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines","volume":"163","author":"Sch\u00fcnemann","year":"2015","journal-title":"Ann Intern Med"},{"key":"2020011013391107100_B5","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"2020011013391107100_B6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6963-4-38","article-title":"Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group","volume":"4","author":"Atkins","year":"2004","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"2020011013391107100_B7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"7650","key":"2020011013391107100_B8","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7","key":"2020011013391107100_B9","first-page":"677","article-title":"Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations","volume":"169","author":"Schunemann","year":"2003","journal-title":"CMAJ"},{"key":"2020011013391107100_B10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jclinepi.2016.01.032","article-title":"GRADE guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health","volume":"76","author":"Sch\u00fcnemann","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"2020011013391107100_B11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1600-0609.2009.01247.x","article-title":"The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review","volume":"83","author":"Abrahamson","year":"2009","journal-title":"Eur J Haematol"},{"issue":"2","key":"2020011013391107100_B12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2009.07615.x","article-title":"Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database","volume":"145","author":"Schoonen","year":"2009","journal-title":"Br J Haematol"},{"issue":"11","key":"2020011013391107100_B13","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/j.1538-7836.2006.02147.x","article-title":"Prevalence of immune thrombocytopenia: analyses of administrative data","volume":"4","author":"Segal","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2020011013391107100_B14","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ajh.21616","article-title":"The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports","volume":"85","author":"Terrell","year":"2010","journal-title":"Am J Hematol"},{"issue":"6","key":"2020011013391107100_B15","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1365-2141.2010.08176.x","article-title":"Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database","volume":"149","author":"Yong","year":"2010","journal-title":"Br J Haematol"},{"key":"2020011013391107100_B16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jclinepi.2016.07.006","article-title":"Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group","volume":"80","author":"Guyatt","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"26","key":"2020011013391107100_B17","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1182\/blood-2009-01-129155","article-title":"The ITP syndrome: pathogenic and clinical diversity","volume":"113","author":"Cines","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2020011013391107100_B18","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26736","article-title":"Predictors of remission in children with newly diagnosed immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group Registry II participants","volume":"65","author":"Bennett","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2020011013391107100_B19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/pbc.20453","article-title":"Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS)","volume":"46","author":"Imbach","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2020011013391107100_B20","first-page":"1041","article-title":"The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy","volume":"91","author":"Sailer","year":"2006","journal-title":"Haematologica"},{"issue":"1","key":"2020011013391107100_B21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V88.1.3.3","article-title":"Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology","volume":"88","author":"George","year":"1996","journal-title":"Blood"},{"issue":"5","key":"2020011013391107100_B22","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0002-9343(99)80342-8","article-title":"Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"1995","journal-title":"Am J Med"},{"issue":"6","key":"2020011013391107100_B23","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajh.25086","article-title":"A comparative prospective observational study of children and adults with immune thrombocytopenia: 2-year follow-up","volume":"93","author":"Schifferli","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"2020011013391107100_B24","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/pbc.21978","article-title":"Relationships among bleeding severity, health-related quality of life, and platelet count in children with immune thrombocytopenic purpura","volume":"53","author":"Neunert","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2020011013391107100_B25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/jth.12813","article-title":"Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review","volume":"13","author":"Neunert","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2020011013391107100_B26","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2008-03-138487","article-title":"Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura","volume":"112","author":"Neunert","year":"2008","journal-title":"Blood"},{"issue":"23","key":"2020011013391107100_B27","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1182\/blood-2009-04-215525","article-title":"Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases","volume":"114","author":"Psaila","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2020011013391107100_B28","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/bjh.12869","article-title":"Twenty-year mortality of adult patients with primary immune thrombocytopenia: a Danish population-based cohort study","volume":"166","author":"Frederiksen","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"2020011013391107100_B29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/ajh.23163","article-title":"Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care","volume":"87","author":"Kuter","year":"2012","journal-title":"Am J Hematol"},{"issue":"10","key":"2020011013391107100_B30","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1185\/03007990802377461","article-title":"Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey","volume":"24","author":"Snyder","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"2020011013391107100_B31","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1600-0609.2011.01587.x","article-title":"Fatigue in adult patients with primary immune thrombocytopenia","volume":"86","author":"Newton","year":"2011","journal-title":"Eur J Haematol"},{"issue":"2","key":"2020011013391107100_B32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjh.13385","article-title":"Fatigue in immune thrombocytopenia","volume":"170","author":"Hill","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"2020011013391107100_B33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/08880010903426767","article-title":"Fatigue as marker of thrombocytopenia in childhood idiopathic thrombocytopenic purpura","volume":"27","author":"Blatt","year":"2010","journal-title":"Pediatr Hematol Oncol"},{"key":"2020011013391107100_B34","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/PROM.S140932","article-title":"Immune thrombocytopenia: improving quality of life and patient outcomes","volume":"9","author":"Trotter","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"issue":"5","key":"2020011013391107100_B35","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1067\/S0022-3476(03)00535-3","article-title":"A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group","volume":"143","author":"K\u00fchne","year":"2003","journal-title":"J Pediatr"},{"issue":"2","key":"2020011013391107100_B36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/03007995.2017.1360852","article-title":"Rate of bleeding-related episodes in elderly patients with primary immune thrombocytopenia: a retrospective cohort study","volume":"34","author":"Li","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"2020011013391107100_B37","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","article-title":"Pathogenesis of immune thrombocytopenia","volume":"16","author":"Audia","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2020011013391107100_B38","volume-title":"Conflict of Interest in Medical Research, Education, and Practice","author":"Institute of Medicine (US) Committee on Conflict of Interest in Medical Research, Education, and Practice","year":"2009"},{"issue":"11","key":"2020011013391107100_B39","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jclinepi.2014.05.006","article-title":"Considering intellectual, in addition to financial, conflicts of interest proved important in a clinical practice guideline: a descriptive study","volume":"67","author":"Akl","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"2020011013391107100_B40","doi-asserted-by":"crossref","first-page":"738","DOI":"10.7326\/0003-4819-152-11-201006010-00254","article-title":"The vexing problem of guidelines and conflict of interest: a potential solution","volume":"152","author":"Guyatt","year":"2010","journal-title":"Ann Intern Med"},{"issue":"6","key":"2020011013391107100_B41","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1164\/rccm.200901-0126ST","article-title":"An official American Thoracic Society Policy statement: managing conflict of interest in professional societies","volume":"180","author":"Sch\u00fcnemann","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"16","key":"2020011013391107100_B42","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2020011013391107100_B43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"2020011013391107100_B44","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2020011013391107100_B45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2016.01.062","article-title":"Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health","volume":"76","author":"Caplan","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2020011013391107100_B46","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000362529","article-title":"Long-term effect of high-dose dexamethasone with or without low-dose dexamethasone maintenance in untreated immune thrombocytopenia","volume":"133","author":"Din","year":"2015","journal-title":"Acta Haematol"},{"issue":"6","key":"2020011013391107100_B47","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1538-7836.2009.03359.x","article-title":"Faster platelet recovery by high-dose dexamethasone compared with standard-dose prednisolone in adult immune thrombocytopenia: a prospective randomized trial","volume":"7","author":"Praituan","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2020011013391107100_B48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2008-2231-20-7","article-title":"Single course of high dose dexamethasone is more effective than conventional prednisolone therapy in the treatment of primary newly diagnosed immune thrombocytopenia","volume":"20","author":"Mashhadi","year":"2012","journal-title":"Daru"},{"issue":"1","key":"2020011013391107100_B49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0002-9343(94)90048-5","article-title":"Intravenous gammaglobulin has no advantages over oral corticosteroids as primary therapy for adults with immune thrombocytopenia: a prospective randomized clinical trial","volume":"97","author":"Jacobs","year":"1994","journal-title":"Am J Med"},{"issue":"3","key":"2020011013391107100_B50","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2015-07-659656","article-title":"High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial","volume":"127","author":"Wei","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2020011013391107100_B51","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/0002-9343(80)90016-9","article-title":"Adult idiopathic thrombocytopenic purpura. Clinical findings and response to therapy","volume":"69","author":"DiFino","year":"1980","journal-title":"Am J Med"},{"issue":"12","key":"2020011013391107100_B52","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00277-008-0537-1","article-title":"Platelet production rate predicts the response to prednisone therapy in patients with idiopathic thrombocytopenic purpura","volume":"87","author":"Houwerzijl","year":"2008","journal-title":"Ann Hematol"},{"issue":"2","key":"2020011013391107100_B53","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000445420","article-title":"A randomized trial of daily prednisone versus pulsed dexamethasone in treatment-naive adult patients with immune thrombocytopenia: EIS 2002 Study","volume":"136","author":"Matschke","year":"2016","journal-title":"Acta Haematol"},{"issue":"4","key":"2020011013391107100_B54","first-page":"329","article-title":"Treatment of idiopathic thrombocytopenic purpura (ITP): results of a multicentric protocol","volume":"70","author":"Mazzucconi","year":"1985","journal-title":"Haematologica"},{"issue":"2","key":"2020011013391107100_B55","first-page":"139","article-title":"Treatment of autoimmune thrombocytopenic purpura","volume":"21","author":"Centurioni","year":"1990","journal-title":"Acta Haematol Pol"},{"issue":"2","key":"2020011013391107100_B56","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2257.2004.00591.x","article-title":"Current management of adult idiopathic thrombocytopenic purpura in practice: a cohort study of 201 patients from a single center","volume":"26","author":"Zimmer","year":"2004","journal-title":"Clin Lab Haematol"},{"issue":"3","key":"2020011013391107100_B57","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-0609.2005.00602.x","article-title":"Idiopathic thrombocytopenic purpura (ITP) in the elderly: clinical course in 178 patients","volume":"76","author":"Bizzoni","year":"2006","journal-title":"Eur J Haematol"},{"issue":"4","key":"2020011013391107100_B58","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"16","key":"2020011013391107100_B59","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids--new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"2020011013391107100_B60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","article-title":"Mechanisms involved in the side effects of glucocorticoids","volume":"96","author":"Sch\u00e4cke","year":"2002","journal-title":"Pharmacol Ther"},{"issue":"10","key":"2020011013391107100_B61","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2352-3026(16)30109-0","article-title":"High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"3","author":"Mithoowani","year":"2016","journal-title":"Lancet Haematol"},{"issue":"21","key":"2020011013391107100_B62","doi-asserted-by":"crossref","first-page":"Abstract 3687","DOI":"10.1182\/blood.V116.21.3687.3687","article-title":"High dose dexamethasone vs. conventional dose prednisolone for adults with immune thrombocytopenia: a prospective multicenter phase III trial [abstract]","volume":"116","author":"Bae","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2020011013391107100_B63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12185-010-0753-z","article-title":"Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia","volume":"93","author":"Li","year":"2011","journal-title":"Int J .Hematol"},{"issue":"14","key":"2020011013391107100_B64","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2009-07-229815","article-title":"Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia","volume":"115","author":"Zaja","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2020011013391107100_B65","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1182\/blood-2012-09-455691","article-title":"Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia","volume":"121","author":"Gudbrandsdottir","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2020011013391107100_B66","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/blood-2011-08-374777","article-title":"A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia","volume":"119","author":"Arnold","year":"2012","journal-title":"Blood"},{"issue":"9978","key":"2020011013391107100_B67","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(14)61495-1","article-title":"Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"385","author":"Ghanima","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"2020011013391107100_B68","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1017\/S0266462313000767","article-title":"Update on romiplostim and eltrombopag indirect comparison","volume":"30","author":"Cooper","year":"2014","journal-title":"Int J Technol Assess Health Care"},{"issue":"3","key":"2020011013391107100_B69","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1017\/S0266462312000414","article-title":"Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison","volume":"28","author":"Cooper","year":"2012","journal-title":"Int J Technol Assess Health Care"},{"key":"2020011013391107100_B70","doi-asserted-by":"crossref","first-page":"39003","DOI":"10.1038\/srep39003","article-title":"Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"issue":"5","key":"2020011013391107100_B71","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jval.2016.03.1856","article-title":"Cost-effectiveness of eltrombopag versus romiplostim for the treatment of chronic immune thrombocytopenia in England and Wales","volume":"19","author":"Allen","year":"2016","journal-title":"Value Health"},{"key":"2020011013391107100_B72","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2147\/CEOR.S177324","article-title":"Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia","volume":"10","author":"Tremblay","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"issue":"9610","key":"2020011013391107100_B73","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"issue":"9763","key":"2020011013391107100_B74","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study [published correction appears in Lancet. 2011;377(9763):382]","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"2020011013391107100_B75","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br J Haematol"},{"issue":"25","key":"2020011013391107100_B76","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1182\/blood-2013-07-514398","article-title":"A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia","volume":"123","author":"Bussel","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2020011013391107100_B77","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ajh.23580","article-title":"Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity","volume":"89","author":"Moulis","year":"2014","journal-title":"Am J Hematol"},{"issue":"5","key":"2020011013391107100_B78","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/SLA.0000000000001912","article-title":"Reemergence of splenectomy for ITP second-line treatment?","volume":"264","author":"Chater","year":"2016","journal-title":"Ann Surg"},{"issue":"9","key":"2020011013391107100_B79","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","article-title":"Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications","volume":"104","author":"Kojouri","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2020011013391107100_B80","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1600-0609.2005.00517.x","article-title":"Splenectomy for adult chronic idiopathic thrombocytopenic purpura: experience from a single center in China","volume":"75","author":"Wang","year":"2005","journal-title":"Eur J Haematol"},{"issue":"1","key":"2020011013391107100_B81","first-page":"72","article-title":"Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases","volume":"90","author":"Vianelli","year":"2005","journal-title":"Haematologica"},{"issue":"5","key":"2020011013391107100_B82","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.amjsurg.2007.02.002","article-title":"An 18-year review of open and laparoscopic splenectomy for idiopathic thrombocytopenic purpura","volume":"193","author":"Sampath","year":"2007","journal-title":"Am J Surg"},{"issue":"3","key":"2020011013391107100_B83","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/ejh.12146","article-title":"Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia","volume":"91","author":"Gonzalez-Porras","year":"2013","journal-title":"Eur J Haematol"},{"issue":"9","key":"2020011013391107100_B84","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00277-016-2738-3","article-title":"Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children: splenectomy in ITP","volume":"95","author":"Ahmed","year":"2016","journal-title":"Ann Hematol"},{"issue":"8","key":"2020011013391107100_B85","first-page":"1175","article-title":"Laparoscopic splenectomy for immune thrombocytopenic purpura at a teaching institution","volume":"124","author":"Zheng","year":"2011","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"2020011013391107100_B86","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/ejh.12821","article-title":"Long-term results of splenectomy in adult chronic immune thrombocytopenia","volume":"98","author":"Guan","year":"2017","journal-title":"Eur J Haematol"},{"issue":"3","key":"2020011013391107100_B87","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000442703","article-title":"Clinical outcome and predictive factors in the response to splenectomy in elderly patients with primary immune thrombocytopenia: a multicenter retrospective study","volume":"135","author":"Park","year":"2016","journal-title":"Acta Haematol"},{"issue":"1","key":"2020011013391107100_B88","first-page":"34","article-title":"Chronic idiopathic thrombocytopenic purpura in adult Chinese patients: a retrospective single-centered analysis of 1791 cases","volume":"118","author":"Li","year":"2005","journal-title":"Chin Med J (Engl)"},{"issue":"7","key":"2020011013391107100_B89","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1089\/lap.2013.0267","article-title":"Laparoscopic splenectomy for primary immune thrombocytopenia: clinical outcome and prognostic factors","volume":"24","author":"Montalvo","year":"2014","journal-title":"J Laparoendosc Adv Surg Tech A"},{"issue":"8","key":"2020011013391107100_B90","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1007\/s00464-005-0445-6","article-title":"Predictive factors for successful laparoscopic splenectomy in immune thrombocytopenic purpura: study of clinical and laboratory data","volume":"20","author":"Balagu\u00e9","year":"2006","journal-title":"Surg Endosc"},{"issue":"7","key":"2020011013391107100_B91","first-page":"914","article-title":"Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura","volume":"90","author":"Wang","year":"2005","journal-title":"Haematologica"},{"issue":"17","key":"2020011013391107100_B92","doi-asserted-by":"crossref","first-page":"610","DOI":"10.4253\/wjge.v8.i17.610","article-title":"Laparoscopic splenectomy for primary immune thrombocytopenia: current status and challenges","volume":"8","author":"Zheng","year":"2016","journal-title":"World J Gastrointest Endosc"},{"issue":"16","key":"2020011013391107100_B93","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa054626","article-title":"AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP","volume":"355","author":"Bussel","year":"2006","journal-title":"N Engl J Med"},{"issue":"22","key":"2020011013391107100_B94","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N Engl J Med"},{"issue":"9664","key":"2020011013391107100_B95","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","article-title":"Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial","volume":"373","author":"Bussel","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"2020011013391107100_B96","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12185-011-0886-8","article-title":"Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized phase III clinical trial","volume":"94","author":"Shirasugi","year":"2011","journal-title":"Int J Hematol"},{"issue":"5","key":"2020011013391107100_B97","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1538-7836.2012.04695.x","article-title":"A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia","volume":"10","author":"Tomiyama","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2020011013391107100_B98","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/bjh.14380","article-title":"Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia","volume":"176","author":"Yang","year":"2017","journal-title":"Br J Haematol"},{"issue":"20","key":"2020011013391107100_B99","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","article-title":"Romiplostim or standard of care in patients with immune thrombocytopenia","volume":"363","author":"Kuter","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"2020011013391107100_B100","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood-2014-06-581868","article-title":"A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP","volume":"125","author":"Zhou","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2020011013391107100_B101","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood-2008-01-131029","article-title":"Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study","volume":"112","author":"Godeau","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2020011013391107100_B102","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjh.13029","article-title":"A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study)","volume":"167","author":"Tran","year":"2014","journal-title":"Br J Haematol"},{"issue":"2","key":"2020011013391107100_B103","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2141.2004.04889.x","article-title":"The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura","volume":"125","author":"Cooper","year":"2004","journal-title":"Br J Haematol"},{"issue":"22","key":"2020011013391107100_B104","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2014-06-582346","article-title":"Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients","volume":"124","author":"Khellaf","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2020011013391107100_B105","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjh.13827","article-title":"Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study","volume":"172","author":"Newland","year":"2016","journal-title":"Br J Haematol"},{"issue":"7","key":"2020011013391107100_B106","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"2020011013391107100_B107","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ajh.25444","article-title":"Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program","volume":"94","author":"Bussel","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"2020011013391107100_B108","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0022-3476(05)80400-7","article-title":"A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura","volume":"123","author":"Blanchette","year":"1993","journal-title":"J Pediatr"},{"issue":"3","key":"2020011013391107100_B109","first-page":"376","article-title":"A prospective, randomized trial of conventional, dose-accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura","volume":"72","author":"Fujisawa","year":"2000","journal-title":"Int J Hematol"},{"issue":"2","key":"2020011013391107100_B110","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00043426-198406020-00008","article-title":"Steroid treatment of idiopathic thrombocytopenic purpura in children. Preliminary results of a randomized cooperative study","volume":"6","author":"Sartorius","year":"1984","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"4","key":"2020011013391107100_B111","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00043426-198424000-00001","article-title":"Prednisone therapy for children with newly diagnosed idiopathic thrombocytopenic purpura. A randomized clinical trial","volume":"6","author":"Buchanan","year":"1984","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"suppl 1","key":"2020011013391107100_B112","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000466426","article-title":"A multicenter European trial of intravenous immune globulin in immune thrombocytopenic purpura in childhood","volume":"49","author":"Imbach","year":"1985","journal-title":"Vox Sang"},{"issue":"8924","key":"2020011013391107100_B113","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0140-6736(94)92205-5","article-title":"Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura","volume":"344","author":"Blanchette","year":"1994","journal-title":"Lancet"},{"issue":"5","key":"2020011013391107100_B114","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1600-0609.1989.tb01466.x","article-title":"High-dose intravenous methylprednisolone for acute childhood idiopathic thrombocytopenic purpura","volume":"42","author":"Ozsoylu","year":"1989","journal-title":"Eur J Haematol"},{"issue":"5","key":"2020011013391107100_B115","first-page":"226","article-title":"A comparative study of initial use of intravenous immunoglobulin and prednisolone treatments in childhood idiopathic thrombocytopenic purpur","volume":"47","author":"Ou","year":"2006","journal-title":"Acta Paediatr Taiwan"},{"issue":"3","key":"2020011013391107100_B116","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/08880018809031267","article-title":"Treatment of acute idiopathic thrombocytopenic purpura (AITP): cooperative Italian study group results","volume":"5","author":"Mori","year":"1988","journal-title":"Pediatr Hematol Oncol"},{"issue":"5","key":"2020011013391107100_B117","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1067\/mpd.2000.110123","article-title":"The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment","volume":"137","author":"Dickerhoff","year":"2000","journal-title":"J Pediatr"},{"issue":"4","key":"2020011013391107100_B118","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/08880010252899370","article-title":"Clinical course of children with immune thrombocytopenic purpura treated with intravenous immunoglobulin G or megadose methylprednisolone or observed without therapy","volume":"19","author":"Duru","year":"2002","journal-title":"Pediatr Hematol Oncol"},{"issue":"4","key":"2020011013391107100_B119","first-page":"457","article-title":"Treatment of acute idiopathic thrombocytopenic purpura in children. A retrospective evaluation of 120 cases","volume":"34","author":"Baronci","year":"1998","journal-title":"Ann Ist Super Sanita"},{"issue":"3","key":"2020011013391107100_B120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ajh.20295","article-title":"Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura","volume":"78","author":"Kumar","year":"2005","journal-title":"Am J Hematol"},{"issue":"1","key":"2020011013391107100_B121","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4274\/Tjh.2012.0049","article-title":"Childhood immune thrombocytopenia: long-term follow-up data evaluated by the criteria of the international working group on immune thrombocytopenic purpura","volume":"31","author":"Evim","year":"2014","journal-title":"Turk J Haematol"},{"issue":"6","key":"2020011013391107100_B122","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3109\/08880018.2015.1040931","article-title":"Initial management of childhood acute immune thrombocytopenia: single-center experience of 32 years","volume":"32","author":"Yildiz","year":"2015","journal-title":"Pediatr Hematol Oncol"},{"issue":"8453","key":"2020011013391107100_B123","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0140-6736(85)90400-3","article-title":"Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood","volume":"2","author":"Imbach","year":"1985","journal-title":"Lancet"},{"issue":"4","key":"2020011013391107100_B124","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3109\/08880019309029508","article-title":"Oral megadose methylprednisolone versus intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura","volume":"10","author":"Ozsoylu","year":"1993","journal-title":"Pediatr Hematol Oncol"},{"issue":"8","key":"2020011013391107100_B125","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1651-2227.1996.tb14183.x","article-title":"Randomized trial comparing intravenous immunoglobulin with methylprednisolone pulse therapy in acute idiopathic thrombocytopenic purpura","volume":"85","author":"Rosth\u00f8j","year":"1996","journal-title":"Acta Paediatr"},{"issue":"4","key":"2020011013391107100_B126","first-page":"295","article-title":"A randomized and comparative study of intravenous immunoglobulin and mega dose methylprednisolone treatments in children with acute idiopathic thrombocytopenic purpura","volume":"45","author":"Erduran","year":"2003","journal-title":"Turk J Pediatr"},{"issue":"4","key":"2020011013391107100_B127","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jpeds.2005.11.019","article-title":"Single dose of anti-D immune globulin at 75 microg\/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children","volume":"148","author":"Tarantino","year":"2006","journal-title":"J Pediatr"},{"issue":"4","key":"2020011013391107100_B128","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPH.0b013e31820e2aa5","article-title":"Standard-dose intravenous anti-D immunoglobulin versus intravenous immunoglobulin in the treatment of newly diagnosed childhood primary immune thrombocytopenia","volume":"33","author":"Papagianni","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"2020011013391107100_B129","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s11239-012-0801-z","article-title":"Comparison of anti-D immunoglobulin, methylprednisolone, or intravenous immunoglobulin therapy in newly diagnosed pediatric immune thrombocytopenic purpura","volume":"35","author":"Celik","year":"2013","journal-title":"J Thromb Thrombolysis"},{"issue":"10","key":"2020011013391107100_B130","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/00043426-200310000-00011","article-title":"Low-dose versus high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children: results of a prospective, randomized single-center trial","volume":"25","author":"Benesch","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"issue":"9","key":"2020011013391107100_B131","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2018-02-830844","article-title":"Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial","volume":"132","author":"Heitink-Poll\u00e9","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2020011013391107100_B132","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s12098-008-0243-y","article-title":"Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura","volume":"75","author":"Shahgholi","year":"2008","journal-title":"Indian J Pediatr"},{"issue":"4","key":"2020011013391107100_B133","first-page":"10","article-title":"Comparison of intravenous immunoglobulin (IVIG) and intravenous anti-D for treatment of acute idiopathic thrombocytopenic purpura","volume":"4","author":"Farahmandinia","year":"2010","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"8","key":"2020011013391107100_B134","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/MPH.0b013e31817541ba","article-title":"A single dose of anti-D immunoglobulin raises platelet count as efficiently as intravenous immunoglobulin in newly diagnosed immune thrombocytopenic purpura in Korean children","volume":"30","author":"Son","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"issue":"12","key":"2020011013391107100_B135","first-page":"FC12","article-title":"High dose intravenous anti-D immune globulin is more effective and safe in Indian paediatric patients of immune thrombocytopenic purpura","volume":"10","author":"Swain","year":"2016","journal-title":"J Clin Diagn Res"},{"issue":"6","key":"2020011013391107100_B136","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/08880010290097161","article-title":"Anti-D exerts a very early response in childhood acute idiopathic thrombocytopenic purpura","volume":"19","author":"Moser","year":"2002","journal-title":"Pediatr Hematol Oncol"},{"issue":"1","key":"2020011013391107100_B137","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2010-10-313908","article-title":"A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia","volume":"118","author":"Bussel","year":"2011","journal-title":"Blood"},{"issue":"10004","key":"2020011013391107100_B138","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","article-title":"Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial [published correction appears in Lancet. 2015;386(10004):1630]","volume":"386","author":"Grainger","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"2020011013391107100_B139","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00277-011-1172-9","article-title":"Romiplostim in children with chronic refractory ITP: randomized placebo controlled study","volume":"90","author":"Elalfy","year":"2011","journal-title":"Ann Hematol"},{"issue":"8","key":"2020011013391107100_B140","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S2352-3026(15)00114-3","article-title":"Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study","volume":"2","author":"Bussel","year":"2015","journal-title":"Lancet Haematol"},{"issue":"10039","key":"2020011013391107100_B141","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0140-6736(16)00279-8","article-title":"Romiplostim in children with immune thrombocytopenia: a phase 3, randomized, double-blind, placebo-controlled study","volume":"388","author":"Tarantino","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"2020011013391107100_B142","doi-asserted-by":"crossref","first-page":"e36698","DOI":"10.1371\/journal.pone.0036698","article-title":"Rituximab for children with immune thrombocytopenia: a systematic review","volume":"7","author":"Liang","year":"2012","journal-title":"PLoS One"},{"issue":"13","key":"2020011013391107100_B143","first-page":"2379","article-title":"Efficacy of standard dose rituximab for refractory idiopathic thrombocytopenic purpura in children","volume":"19","author":"Dai","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"7","key":"2020011013391107100_B144","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2005-08-3518","article-title":"Prospective phase 1\/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura","volume":"107","author":"Bennett","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2020011013391107100_B145","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/pbc.23130","article-title":"Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia","volume":"58","author":"Grace","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"10039","key":"2020011013391107100_B146","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0140-6736(16)00279-8","article-title":"Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"Tarantino","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"2020011013391107100_B147","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/pbc.21108","article-title":"Splenectomy in children with idiopathic thrombocytopenic purpura: a prospective study of 134 children from the Intercontinental Childhood ITP Study Group","volume":"49","author":"K\u00fchne","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2020011013391107100_B148","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1542\/peds.111.1.87","article-title":"Response to intravenous immunoglobulin predicts splenectomy response in children with immune thrombocytopenic purpura [published correction appears in Pediatrics. 2004;113(1):184]","volume":"111","author":"Holt","year":"2003","journal-title":"Pediatrics"},{"issue":"1","key":"2020011013391107100_B149","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1600-0609.1984.tb00684.x","article-title":"Long-term follow-up study of 168 patients with immune thrombocytopenia. Implications for therapy","volume":"32","author":"den Ottolander","year":"1984","journal-title":"Scand J Haematol"},{"issue":"1","key":"2020011013391107100_B150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000072409","article-title":"5- to 16-year follow-up following splenectomy in chronic immune thrombocytopenic purpura in children","volume":"110","author":"El-Alfy","year":"2003","journal-title":"Acta Haematol"},{"issue":"1-2","key":"2020011013391107100_B151","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000089464","article-title":"Splenectomy for chronic idiopathic thrombocytopenic purpura in children: a single center study in China","volume":"115","author":"Wang","year":"2006","journal-title":"Acta Haematol"},{"issue":"5","key":"2020011013391107100_B152","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1651-2227.2004.tb02989.x","article-title":"Retrospective evaluation of long-term efficacy and safety of splenectomy in chronic idiopathic thrombocytopenic purpura in children","volume":"93","author":"Aronis","year":"2004","journal-title":"Acta Paediatr"},{"issue":"6","key":"2020011013391107100_B153","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF00320313","article-title":"Recurrence of thrombocytopenia in patients splenectomized for idiopathic thrombocytopenic purpura","volume":"43","author":"Pawelski","year":"1981","journal-title":"Blut"},{"issue":"4","key":"2020011013391107100_B154","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0022-3468(91)90987-5","article-title":"Immune thrombocytopenia: surgical therapy and predictors of response","volume":"26","author":"Davis","year":"1991","journal-title":"J Pediatr Surg"},{"issue":"4","key":"2020011013391107100_B155","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/adc.59.4.316","article-title":"Idiopathic thrombocytopenia, initial illness and long term follow up","volume":"59","author":"Walker","year":"1984","journal-title":"Arch Dis Child"},{"issue":"2","key":"2020011013391107100_B156","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00043426-200003000-00013","article-title":"Elective splenectomy in children with idiopathic thrombocytopenic purpura","volume":"22","author":"Mantadakis","year":"2000","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"2020011013391107100_B157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000204251","article-title":"Clinical and therapeutic experience in 712 Israeli patients with idiopathic thrombocytopenic purpura","volume":"91","author":"Ben-Yehuda","year":"1994","journal-title":"Acta Haematol"},{"issue":"2","key":"2020011013391107100_B158","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/MPH.0b013e3180320b36","article-title":"Chronic immune thrombocytopenic purpura in children: a survey of the Canadian experience","volume":"29","author":"Belletrutti","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"2020011013391107100_B159","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.surg.2011.07.063","article-title":"Predictive value of response to steroid therapy on response to splenectomy in children with immune thrombocytopenic purpura","volume":"150","author":"Hollander","year":"2011","journal-title":"Surgery"},{"issue":"suppl 5","key":"2020011013391107100_B160","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/pbc.20978","article-title":"Splenectomy in children with chronic ITP: long-term efficacy and relation between its outcome and responses to previous treatments","volume":"47","author":"Ramenghi","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2020011013391107100_B161","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00383-006-1717-5","article-title":"Pediatric splenectomy for hematological diseases: outcome analysis","volume":"22","author":"Durakbasa","year":"2006","journal-title":"Pediatr Surg Int"},{"issue":"8","key":"2020011013391107100_B162","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1177\/000992280404300802","article-title":"Idiopathic thrombocytopenic purpura: a 10-year natural history study at the Childrens Hospital of Alabama","volume":"43","author":"Watts","year":"2004","journal-title":"Clin Pediatr (Phila)"},{"issue":"1","key":"2020011013391107100_B163","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.2830010111","article-title":"Treatment of refractory thrombocytopenic purpura with cyclophosphamine","volume":"1","author":"Verlin","year":"1976","journal-title":"Am J Hematol"},{"issue":"6","key":"2020011013391107100_B164","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1182\/blood.V64.6.1179.1179","article-title":"Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: multicentric trial of the Cooperative Latin American Group on Hemostasis and Thrombosis","volume":"64","author":"Pizzuto","year":"1984","journal-title":"Blood"},{"issue":"3","key":"2020011013391107100_B165","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1651-2227.1982.tb09453.x","article-title":"Immunosuppressive treatment of idiopathic thrombocytopenic purpura in children","volume":"71","author":"Joseph","year":"1982","journal-title":"Acta Paediatr Scand"},{"issue":"10","key":"2020011013391107100_B166","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.3324\/haematol.13481","article-title":"Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura","volume":"93","author":"Choudhary","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"2020011013391107100_B167","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1046\/j.1365-2141.2001.02893.x","article-title":"Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy","volume":"114","author":"Kappers-Klunne","year":"2001","journal-title":"Br J Haematol"},{"issue":"11","key":"2020011013391107100_B168","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00277-016-2791-y","article-title":"Cyclosporin A for persistent or chronic immune thrombocytopenia in children","volume":"95","author":"Liu","year":"2016","journal-title":"Ann Hematol"},{"issue":"1","key":"2020011013391107100_B169","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1365-2141.2003.04254.x","article-title":"Treatment with short-term, high-dose cyclosporin A in children with refractory chronic idiopathic thrombocytopenic purpura","volume":"121","author":"Perrotta","year":"2003","journal-title":"Br J Haematol"},{"key":"2020011013391107100_B170","doi-asserted-by":"crossref","first-page":"548085","DOI":"10.1155\/2013\/548085","article-title":"Effects of rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia","volume":"2013","author":"Li","year":"2013","journal-title":"Clin Dev Immunol"},{"issue":"2","key":"2020011013391107100_B171","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1096\/fasebj.3.2.2914627","article-title":"Danazol therapy renders red cells resistant to osmotic lysis","volume":"3","author":"Ahn","year":"1989","journal-title":"FASEB J"},{"issue":"5","key":"2020011013391107100_B172","first-page":"275","article-title":"Therapeutic effect of danazol on metrorrhagia in patients with idiopathic thrombocytopenic purpura (ITP)","volume":"28","author":"Ambr\u00edz","year":"1986","journal-title":"Nouv Rev Fr Hematol"},{"issue":"2","key":"2020011013391107100_B173","first-page":"143","article-title":"The role of danazol in the treatment of refractory idiopathic thrombocytopenic purpura. A report of 22 cases","volume":"32","author":"Fenaux","year":"1990","journal-title":"Nouv Rev Fr Hematol"},{"issue":"8","key":"2020011013391107100_B174","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/1076029615622002","article-title":"The effect of danazol in primary immune thrombocytopenia: an analysis of a large cohort from a single center in China","volume":"22","author":"Liu","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"issue":"9","key":"2020011013391107100_B175","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.amjmed.2003.12.024","article-title":"Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results","volume":"116","author":"Maloisel","year":"2004","journal-title":"Am J Med"},{"issue":"5","key":"2020011013391107100_B176","first-page":"350","article-title":"Danazol therapy in chronic idiopathic thrombocytopenic purpura","volume":"40","author":"Sundar","year":"1992","journal-title":"J Assoc Physicians India"},{"issue":"2","key":"2020011013391107100_B177","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12185-012-1124-8","article-title":"A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia","volume":"96","author":"Wang","year":"2012","journal-title":"Int J Hematol"},{"issue":"4","key":"2020011013391107100_B178","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/107602969700300406","article-title":"Efficacy of danazol with autoimmune thrombocytopenia","volume":"3","author":"Kim","year":"1997","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"2020011013391107100_B179","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1600-0609.2005.00545.x","article-title":"Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults--a report on 90 patients","volume":"75","author":"Damodar","year":"2005","journal-title":"Eur J Haematol"},{"issue":"2","key":"2020011013391107100_B180","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1046\/j.1365-2141.1997.412687.x","article-title":"Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases","volume":"97","author":"Godeau","year":"1997","journal-title":"Br J Haematol"},{"issue":"2","key":"2020011013391107100_B181","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3109\/09537104.2014.886677","article-title":"Dapsone for immune thrombocytopenic purpura in children and adults","volume":"26","author":"Patel","year":"2015","journal-title":"Platelets"},{"issue":"7","key":"2020011013391107100_B182","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/09537100802315110","article-title":"Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura","volume":"19","author":"Vancine-Califani","year":"2008","journal-title":"Platelets"},{"issue":"3","key":"2020011013391107100_B183","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/ajh.22266","article-title":"Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab","volume":"87","author":"Zaja","year":"2012","journal-title":"Am J Hematol"},{"issue":"6","key":"2020011013391107100_B184","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1034\/j.1600-0609.2003.00076.x","article-title":"Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura","volume":"70","author":"Hou","year":"2003","journal-title":"Eur J Haematol"},{"issue":"3","key":"2020011013391107100_B185","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/bjh.14261","article-title":"Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology\/oncology","volume":"175","author":"Miano","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2020011013391107100_B186","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bjh.13622","article-title":"Mycophenolate mofetil therapy for severe immune thrombocytopenia","volume":"171","author":"Taylor","year":"2015","journal-title":"Br J Haematol"},{"issue":"5","key":"2020011013391107100_B187","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1745-7254.2005.00088.x","article-title":"Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura","volume":"26","author":"Zhang","year":"2005","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"2020011013391107100_B188","doi-asserted-by":"crossref","first-page":"192","DOI":"10.7326\/0003-4819-100-2-192","article-title":"Slow infusion of vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura","volume":"100","author":"Ahn","year":"1984","journal-title":"Ann Intern Med"},{"issue":"8","key":"2020011013391107100_B189","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1056\/NEJM197408222910802","article-title":"Vincristine therapy of idiopathic and secondary thrombocytopenias","volume":"291","author":"Ahn","year":"1974","journal-title":"N Engl J Med"},{"issue":"3","key":"2020011013391107100_B190","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1365-2141.1994.tb04810.x","article-title":"A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients","volume":"86","author":"Facon","year":"1994","journal-title":"Br J Haematol"},{"issue":"4","key":"2020011013391107100_B191","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/BF01728791","article-title":"Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic purpura: a report on 43 cases","volume":"60","author":"Fenaux","year":"1990","journal-title":"Blut"},{"issue":"9","key":"2020011013391107100_B192","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/ajh.22081","article-title":"Vinblastine in the treatment of children and adolescents with refractory immune thrombocytopenia","volume":"86","author":"Fresneau","year":"2011","journal-title":"Am J Hematol"},{"issue":"4","key":"2020011013391107100_B193","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1445-5994.1991.tb01339.x","article-title":"Targeted-immunosuppression with vincristine infusion in the treatment of immune thrombocytopenia","volume":"21","author":"Manoharan","year":"1991","journal-title":"Aust N Z J Med"},{"issue":"7","key":"2020011013391107100_B194","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJM197708182970718","article-title":"More on vincristine in treatment of ITP in children","volume":"297","author":"Massimo","year":"1977","journal-title":"N Engl J Med"},{"issue":"1","key":"2020011013391107100_B195","first-page":"98","article-title":"Clinical usefulness of vinca alkaloid slow infusion in the treatment of chronic refractory idiopathic thrombocytopenic purpura: a multicenter cooperative study","volume":"53","author":"Nomura","year":"1990","journal-title":"Nippon Ketsueki Gakkai Zasshi"},{"issue":"2","key":"2020011013391107100_B196","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12185-015-1903-0","article-title":"Clinical efficacy and tolerability of vincristine in splenectomized patients with refractory or relapsed immune thrombocytopenia: a retrospective single-center study","volume":"103","author":"Park","year":"2016","journal-title":"Int J Hematol"},{"issue":"6","key":"2020011013391107100_B197","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2257.2004.00643.x","article-title":"The use of vinca alkaloids in adult patients with refractory chronic idiopathic thrombocytopenia","volume":"26","author":"Sikorska","year":"2004","journal-title":"Clin Lab Haematol"},{"issue":"1","key":"2020011013391107100_B198","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1750-1172-7-77","article-title":"The French Gaucher\u2019s disease registry: clinical characteristics, complications and treatment of 562 patients","volume":"7","author":"Stirnemann","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"20","key":"2020011013391107100_B199","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJM197805182982001","article-title":"The treatment of idiopathic thrombocytopenia with vinblastine-loaded platelets","volume":"298","author":"Ahn","year":"1978","journal-title":"N Engl J Med"},{"issue":"suppl 5","key":"2020011013391107100_B200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000492187","article-title":"Immune thrombocytopenia - current diagnostics and therapy: recommendations of a joint working group of DGHO, \u00d6GHO, SGH, GPOH, and DGTI","volume":"41","author":"Matzdorff","year":"2018","journal-title":"Oncol Res Treat"},{"key":"2020011013391107100_B201","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jclinepi.2016.09.009","article-title":"GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT","volume":"81","author":"Sch\u00fcnemann","year":"2017","journal-title":"J Clin Epidemiol"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2019001380","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/23\/3829\/1551404\/advancesadv2019000966.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/23\/3829\/1551404\/advancesadv2019000966.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T22:52:41Z","timestamp":1722120761000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/23\/3829\/429213\/American-Society-of-Hematology-2019-guidelines-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,3]]},"references-count":201,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2019,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000966","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,3]]}}}